Pyrazolopyridine HPK1 Inhibitors for Antitumor Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that modulate the activity of hematopoietic progenitor kinase 1 (HPK1) to enhance antitumor immunity and address autoimmune diseases, as existing treatments are inadequate.
Innovation Solution
Development of pyrazolopyridine compounds that inhibit HPK1 activity, which can be administered to individuals to treat diseases by modulating immune cell functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used, then current therapeutic approaches are maintained, but they are inadequate for enhancing antitumor immunity and treating autoimmune diseases
Solution Approach 1:
The patent applies parameter changes by developing novel pyrazolopyridine compounds with specific molecular structures (Formula I) that differ from existing treatments. These compounds modify the chemical parameters of HPK1 inhibition to achieve enhanced therapeutic effectiveness for antitumor immunity and autoimmune diseases, directly addressing the inadequacy of current therapies
2Reliability
If HPK1 activity is inhibited, then antitumor immunity is enhanced and autoimmune diseases are treated, but new compounds need to be developed
Solution Approach 1:
The patent segments the HPK1 kinase structure into specific binding regions and develops pyrazolopyridine compounds (Formula I) with tailored molecular segments that selectively inhibit HPK1. This segmentation approach enables the design of compounds with optimized immune modulation effectiveness while establishing a systematic method for their production
Solution Approach 2:
The pyrazolopyridine compounds act as intermediary molecules that mediate the inhibition between the drug delivery system and the HPK1 target. These compounds serve as the critical link that translates the therapeutic goal of HPK1 inhibition into actual immune modulation, addressing both effectiveness and manufacturability
Data Source
AI summary
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with HPK1 activity such as cancer.